Kraft Heinz Co vs uniQure N.V. Ordinary Shares — how do they compare? Kraft Heinz Co trades at $22.99 (market cap $26.60B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Kraft Heinz Co is far larger — about 18× uniQure N.V. Ordinary Shares's market cap, and Kraft Heinz Co pays a 7.13% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| KHC | QURE | |
|---|---|---|
Market Cap | $26.60B | $1.48B |
Volume | 11,136,448 | 2,488,780 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $70.59 |
52-Week Low | $21.21 | $9.03 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $42.92B | $728.62M |
Dividend Yield | 7.13% | — |
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.43, down 0.09% with bearish technical signals despite recent earnings beats. The company faces fundamental challenges with a net loss of $5.85 billion in 2025 and negative profit margins, though operating cash flow remains strong at $4.46 billion. Recent news highlights ongoing turnaround efforts including new product launches and a $700 million reinvestment strategy to revive brands.
The stock presents a mixed outlook with attractive valuation metrics (P/E 13.04, P/B 0.74) and 6.5% dividend yield, but significant execution risks persist. Analyst consensus leans cautious with 57% hold ratings, while institutional interest remains with recent large purchases. Key risks include continued volume declines, high debt load, and competitive pressures in the consumer goods sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →